GLP1R and Insulin resistance: The activation of AHR caused the upregulation of GLP-1 and IL-22 at proteins and mRNA levels, decreased systemic LPS, improved gut barrier function, activated the hepatic STAT3/IL-22R/peroxisomal acyl-coenzyme A oxidase 1 (ACOX1) and pancreatic GLP-1R/p-CREB signaling pathways, and improved lipid metabolism and insulin resistance.